Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662139 | 0.84 | CA12 (0.52) | CA9CA12CA2KDM4EALDH1A1 | |
| SCHEMBL2117997 | 0.80 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDTP53KMT2A | |
| SCHEMBL4253425 | 0.79 | KDM4E (0.79) | KDM4EALDH1A1HPGDTP53KMT2A | |
| SCHEMBL6973438 | 0.78 | HSD17B10 (0.66) | KDM4EALDH1A1HPGDTP53KMT2A | |
| SCHEMBL7467623 | 0.78 | CMA1 (0.75) | CA9CA12CA2KDM4EALDH1A1 | |
| SCHEMBL4254796 | 0.78 | ALDH1A1 (0.79) | KDM4EALDH1A1HPGDTP53KMT2A | |
| SCHEMBL8480237 | 0.76 | MEN1 (0.73) | CA9CA12CA2KDM4EALDH1A1 | |
| SCHEMBL6977596 | 0.76 | KDM4E (0.73) | CA9CA12KDM4EALDH1A1HPGD | |
| SCHEMBL707203 | 0.76 | ADORA3 (0.56) | CA9CA12CA2KDM4EALDH1A1 | |
| SCHEMBL4931135 | 0.76 | GABRP (0.56) | KDM4EALDH1A1HPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | CA9 3816/4885CA12 4672/4885CA2 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.